Treatment of Aortic Disease in Patients With Marfan Syndrome
- 22 March 2005
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 111 (11), e150-e157
- https://doi.org/10.1161/01.cir.0000155243.70456.f4
Abstract
Marfan syndrome (MFS) is a heritable disorder of the connective tissue with a prevalence of ≈1 in 3000 to 5000 individuals. The condition is inherited in an autosomal dominant manner with complete penetrance but demonstrates variable expression with significant intra- and interfamilial variation. Approximately 25% of patients do not have a family history and represent sporadic, new mutations for the condition. The cardinal features of MFS involve the cardiovascular, ocular, and skeletal systems. The most life-threatening complication of MFS is thoracic aortic aneurysms leading to aortic dissection, rupture, or both. This article focuses on medical and surgical treatment of aortic disease in patients with MFS and addresses the treatment of aortic disease in children and pregnant women with the condition. The most common cardiovascular complication in patients with MFS is progressive aortic root enlargement initially occurring at the sinuses of Valsalva. Ascending aortic aneurysm can precipitate acute type A aortic dissection, aortic rupture, aortic regurgitation (AR), or all 3, and these complications were the primary cause of death before the advent of successful preventive therapies. Treatment of the aorta consists of regular imaging to detect and quantify progression of aortic dilation, β-adrenergic receptor antagonist therapy, and prophylactic aortic repair when the dilation reaches a sufficient size to threaten dissection or cause AR. Before the era of open-heart surgery, the majority of patients with MFS died prematurely of rupture of the aorta, with an average life expectancy of 45 years.1 The success of current medical and surgical treatment of aortic disease in MFS has substantially improved the average life expectancy, extending it up to 70 years.2,3 Cardiovascular manifestations in MFS also include valvular disease involving the mitral valve, aortic valve, or both. Mitral valve prolapse is the most prevalent valvular abnormality, affecting 35% to 100% of patients.4 Mitral …This publication has 35 references indexed in Scilit:
- Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndromeNature Genetics, 2003
- Morbidity and mortality after extent II thoracoabdominal aortic aneurysm repairThe Annals of Thoracic Surgery, 2002
- Natural history of cardiovascular manifestations in Marfan syndromeArchives of Disease in Childhood, 2001
- Replacement of the Aortic Root in Patients with Marfan's SyndromeThe New England Journal of Medicine, 1999
- Heterogeneous aortic response to acute β-adrenergic blockade in Marfan syndromeAmerican Heart Journal, 1997
- Delineation of the Marfan phenotype associated with mutations in exons 23–32 of theFBN1 geneAmerican Journal of Medical Genetics, 1996
- Life expectancy in the Marfan syndromeThe American Journal of Cardiology, 1995
- Prognostic significance of the pattern of aortic root dilation in the Marfan syndromeJournal of the American College of Cardiology, 1993
- Two-dimensional echocardiographic aortic root dimensions in normal children and adultsThe American Journal of Cardiology, 1989
- Fibrillin, a new 350-kD glycoprotein, is a component of extracellular microfibrils.The Journal of cell biology, 1986